Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction

SIMPLE SUMMARY: Despite the relationship between Carfilzomib (CFZ) therapy in multiple myeloma (MM) and cardiovascular adverse events (CVAEs), no specific validated protocols on cardiovascular risk assessment are available. In this prospective study, we investigated major predictors of CVAEs prior t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Astarita, Anna, Mingrone, Giulia, Airale, Lorenzo, Vallelonga, Fabrizio, Covella, Michele, Catarinella, Cinzia, Cesareo, Marco, Bruno, Giulia, Leone, Dario, Giordana, Carlo, Cetani, Giusy, Salvini, Marco, Gay, Francesca, Bringhen, Sara, Rabbia, Franco, Veglio, Franco, Milan, Alberto
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8036868/
https://ncbi.nlm.nih.gov/pubmed/33915804
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13071631
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars